title: [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].
abstract: Poxviruses as expression vectors are widely used in medical research for the development of recombinant vaccines and molecular therapies. Here we review recent accomplishments in vaccine research using recombinant modified vaccinia virus ankara (MVA). MVA is a highly attenuated vaccinia virus strain that originated from serial tissue culture passage in chicken embryo fibroblasts more than 40 years ago. Growth adaptation to avian host cells caused deletions and mutations in the viral genome affecting about 15% of the original genetic information. In consequence, MVA is replication-deficient in cells of mammalian origin and fails to produce many of the virulence factors encoded by conventional vaccinia virus. Because of its safety for the general environment MVA can be handled under conditions of biosafety level one. Non-replicating MVA can enter any target cell and activate its molecular life cycle to express all classes of viral and recombinant genes. Therefore, recombinant MVA have been established as an extremely safe and efficient vector system for vaccine development in medical research. By now, various recombinant MVA vaccines have been found safe and immunogenic when used for phase I/II clinical testing in humans, and suitable for industrial scale production following good practice of manufacturing. Thus, there is an obvious usefulness of recombinant MVA vaccines for novel prophylactic and therapeutic approaches also in veterinary medicine. Results from first studies in companion and farm animals are highly promising.
authors.forename: Asisa
authors.initials: A
authors.lastname: Volz
authors.forename: Robert
authors.initials: R
authors.lastname: Fux
authors.forename: Martin C
authors.initials: MC
authors.lastname: Langenmayer
authors.forename: Gerd
authors.initials: G
authors.lastname: Sutter
mesh_terms: D000818:Animals; D000829:Animals, Domestic; D015967:Gene Expression Regulation, Viral; D005822:Genetic Vectors; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000592:standards; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*; D014730:Veterinary Medicine / Q000379:methods*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology
chemical_list: D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines